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Abstract
Background: The blood pressure (BP) of a proportion of chronic hemodialysis (HD) patients rises after HD. We
investigated the influence of postdialysis BP rise on long-term outcomes.
Methods: A total of 115 prevalent HD patients were enrolled. Because of the fluctuating nature of predialysis and
postdialysis BP, systolic BP (SBP) and diastolic BP before and after HD were recorded from 25 consecutive HD
sessions during a 2-month period. Patients were followed for 4 years or until death or withdrawal.
Results: Kaplan-Meier estimates revealed that patients with average postdialysis SBP rise of more than 5 mmHg
were at the highest risk of both cardiovascular and all-cause mortality as compared to those with an average
postdialysis SBP change between -5 to 5 mmHg and those with an average postdialysis SBP drop of more than 5
mmHg. Furthermore, multivariate Cox regression analysis indicated that both postdialysis SBP rise of more than 5
mmHg (HR, 3.925 [95% CI, 1.410-10.846], p = 0.008) and high cardiothoracic (CT) ratio of more than 50% (HR, 7.560
[95% CI, 2.048-27.912], p = 0.002) independently predicted all-cause mortality. We also found that patients with an
average postdialysis SBP rise were associated with subclinical volume overload, as evidenced by the significantly
higher CT ratio (p = 0.008).
Conclusions: A postdialysis SBP rise in HD patients independently predicted 4-year cardiovascular and all-cause
mortality. Considering postdialysis SBP rise was associated with higher CT ratio, intensive evaluation of cardiac and
volume status should be performed in patients with postdialysis SBP rise.
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Background
Due to oliguria or even anuria, most end-stage renal dis-
ease (ESRD) patients undergoing maintenance hemodia-
lysis (HD) require ultrafiltration during HD in order to
maintain a euvolemic status. Although the volume-
dependent component of hypertension may be corrected
by fluid removal, a proportion of HD patients experi-
ence postdialysis BP rise. The underlying mechanisms of
intradialytic hypertension are complex and have been
considered to be caused by clinically silent fluid over-
load, activation of the renin-angiotensin axis, sympa-
thetic overactivity, endothelial dysfunction, and sodium
loading during HD [1-8]. Inrig et al. recently recognized
its association with endothelial cell dysfunction, which
was assessed by peripheral blood endothelial progenitor
cells and ultrasonographic measurement of brachial
artery flow-mediated vasodilation underlie the pathogen-
esis of intradialytic hypertension [9].
Cardiovascular disease is the leading cause of morbid-
ity and mortality in ESRD [10]. Hypertension is highly
prevalent in patients undergoing HD and contributes to
the high cardiovascular morbidity and mortality in these
patients [11]. Postdialysis BP goals should be below 130/
80 mmHg according to the National Kidney Founda-
tion’s Kidney Disease Outcomes Quality Initiative
(KDOQI) recommendation [12]. Surprisingly, little
attention had been paid on postdialysis hypertension
until some recent studies showed its clinical significance
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However, the predictive values of predialysis and post-
dialysis BP have been disputed due to its high variability
nature [14-16], which could be overcome by increasing
the number of BP recording times for more than 1
month [17,18].
Although some studies have demonstrated the adverse
impact of intradialytic hypertension on 2-year all-cause
mortality [1,4], the relationship between postdialysis
hypertension and cardiovascular outcomes was
unknown. We hypothesized that poor overall survival in
such patients is related to volume overload that leading
to future cardiovascular death. We also aimed to eluci-
date whether the adverse outcomes persist with higher
follow-up. Therefore, we followed up our HD patients
for more than 4 years and included cardiovascular mor-
tality in patient outcomes as well.
Methods
Study protocol and subjects
From January 2006 to June 2010, we conducted a pro-
spective observational cohort study at the Taipei Veter-
ans General Hospital, a tertiary-care referral hospital.
Each enrolled subject provided written informed con-
sent, and this study was approved by the Institutional
Review Board of Taipei Veterans General Hospital. All
patients were at least 18 years of age, had ESRD, and
had been on maintenance HD for at least 3 months. At
study entry in 2006, we screened all prevalent HD
patients in our unit (n = 178). We excluded recent
adverse cardiovascular events or hospitalization within 3
months (n = 7), signs of current infection (n = 7), active
autoimmune disease/collagen vascular disease (n =1 ) ,
advanced/severe liver disease (n = 2), patients received
HD only twice weekly (n = 12), and patients who
refused to provide consent (n = 34). Eventually, a total
of 115 prevalent HD patients were enrolled.
At study entry, we recorded predialysis and postdialy-
sis systolic BP (SBP) and diastolic BP (DBP) for 25 con-
secutive HD sessions during a 2-month period. The
demographic features and clinical parameters, including
age, gender, duration of dialysis, body weight index,
comorbidities, nutritional supplements, medications,
serum biochemical data, and blood cell counts were
obtained. Smoking status was defined as never (0), quit
(1), or current smoker (2). Cardiothoracic (CT) ratios
were obtained from postdialysis chest radiographs in a
standing position (posterior-anterior view). The CT ratio
was calculated by dividing the maximal transverse dia-
meter of the cardiac silhoutte by the transverse inner
diameter of the rib cage. It was interpreted by an inde-
pendent radiologist and two independent nephrologists
separately, and was then averaged from three data of
each patient to reflect the volume status.
Dialysis procedures
HD was performed three times weekly (4 hours per ses-
sion) using 1.8-m2 surface area dialyzers with bicarbo-
nate-based dialysates (sodium, 140 mEq/L [mmol/L];
bicarbonate, 39 mEq/L [mmol/L]; potassium, 2.0 mEq/L
[mmol/L]; calcium, 3.0 mEq/L; and magnesium 1.0
mEq/L). All patients were treated with recombinant
human erythropoietin at an average dosage of 20,000
units monthly, with a target hematocrit level of 30-36%.
BP measurements
Brachial artery BP was measured with the mercury
sphygmomanometer in seated position. Predialysis BP
w a sm e a s u r e da tt h eb e g i n n i n go fH Da f t e r1 5m i n u t e s
of quiet rest. Postdialysis BP was measured at the end of
HD 15 minutes after disconnecting from the dialysis cir-
cuit. Both predialysis and postdialysis BP were measured
in the seated position. Mean arterial pressure (MAP)
was calculated as (SBP + 2 × DBP)/3. Pulse pressure
(PP) was calculated from the SBP and DBP (PP = SBP -
DBP). Postdialysis BP rise or drop was defined by the
difference between postdialysis and predialysis BP
values. The variability of postdialysis SBP alteration of
each patient was also examined. We first calculated the
percentage of postdialysis SBP alteration in each HD
sessions as (postdialysis SBP - predialysis SBP)/predialy-
sis SBP * 100%. A total of 25 postdialysis SBP alteration
percentages were obtained from each patient. We
further calculated the standard deviation of these 25
data, which was defined as the variability of postdialysis
SBP alteration of each patient. Ultrafiltration volume
was defined as the amount of fluid removed within an
HD session. All of the BP values and ultrafiltration
volume were averaged from 25 consecutive HD sessions
during a 2-month period.
Laboratory measurements
Blood samples were collected before the mid-week HD
session. Samples were centrifuged within 1 hour of col-
lection and then immediately sent to the central labora-
tory for analysis. Laboratory data were recorded as the
average of 3 months’ data. All measurements were
determined in a single central laboratory.
Clinical outcomes
After baseline assessments, all patients were followed for
4 years or until death. Patients who received a kidney
transplantation were censored at the time of transplan-
tation. Clinical outcomes were death due to non-cardio-
vascular etiologies and cardiovascular diseases, including
acute myocardial infarction, sudden cardiac arrest, fatal
arrhythmia, cardiogenic shock, and stroke. For cardio-
vascular mortality, patients were also censored at the
time of other causes of death. The causes of death were
Yang et al. BMC Nephrology 2012, 13:12
http://www.biomedcentral.com/1471-2369/13/12
Page 2 of 10determined by the attending physicians who had no
knowledge of patient grouping according to postdialysis
BP alterations. In cases of death that did not occur in
our hospital, family members were interviewed by tele-
phone to ascertain the cause and time of death.
Statistical analysis
Chi-square analysis or Fisher’se x a c tt e s tw a su s e df o r
comparison of categorical variables as appropriate. Con-
tinuous variables were compared by analysis of variance
(ANOVA), Student’s t-test, or paired t-test as appropri-
ate. Values of the continuous variables are presented as
mean and standard deviation, unless otherwise specified.
The Cox proportional hazards model was used to deter-
mine the significance of variables in predicting the pri-
mary end-point, including all-cause mortality and
cardiovascular mortality. Variables associated with clini-
cal outcomes in univariate Cox regression analysis with
p values less than 0.10 were used for multivariate Cox
regression analysis. Kaplan-Meier analysis was used to
assess the difference among patients with a postdialysis
BP rise of more than 5 mmHg, those with a postdialysis
SBP change between -5 to 5 mmHg, and those with a
postdialysis BP drop of more than 5 mmHg in reaching
the primary end-point. This comparison was performed
using the log-rank test. SPSS version 15.0 for Windows
(SPSS Inc., Chicago, Illinois, USA) was used for all sta-
tistical analyses. All probabilities were two-tailed and a
p value of less than 0.05 was considered statistically
significant.
Results
Baseline characteristics of study subjects
Table 1 shows the baseline characteristics of the 115
patients who were followed for 4 years. At enrollment,
the mean age was 64 years, 45% of patients were male,
and the mean duration on dialysis was 5.8 years. A total
of 46 patients (40%) had diabetes mellitus, 105 patients
(91%) had hypertension, 30 patients (26%) had cardio-
vascular diseases, 5 patients (4%) had a history of stroke,
and 9 patients (8%) had malignancy. BP before and after
HD and ultrafiltration volume were averaged from 25
consecutive HD sessions during a 2-month period. We
categorized our patients into 3 groups, including
patients with an average postdialysis SBP rise of more
than 5 mmHg (n = 39), those with an average postdialy-
sis SBP change between -5 to 5 mmHg (n =2 7 ) ,a n d
those with an average postdialysis SBP drop of more
than 5 mmHg (n = 49).
Compared to patients with an average postdialysis SBP
change between -5 to 5 mmHg and those with an average
postdialysis SBP drop for more than 5 mmHg, those with
an average postdialysis SBP rise of more than 5 mmHg
were more likely to be older (p = 0.007), have a higher
percentage of antihypertensive agents usage (p = 0.025),
lower hemoglobin level (p = 0.077), smaller ultrafiltration
volume (p = 0.006), and higher CT ratio (p = 0.002).
Figure 1 shows the histogram of postdialysis SBP altera-
tions of 2875 HD sessions in 115 patients. Among all of the
patients, the average SBP of 39 patients (33.9%) rose more
than 5 mmHg after dialysis. In addition, the average MAP
of 31 patients (27.0%), DBP of 23 patients (20.0%), and PP
of 32 patients (27.8%) rose more than 5 mmHg after dialy-
sis. Figure 2 shows the differences between predialysis and
postdialysis BP in patients with an average postdialysis SBP
rise of more than 5 mmHg (n = 39) and those with an aver-
age postdialysis SBP drop of more than 5 mmHg (n =4 9 ) .
For patients with an average postdialysis BP for more than
5 mmHg, the average predialysis BPs were 138 ± 17 mmHg
(range, 103 to 164 mmHg) for SBP, 96 ± 10 mmHg (range,
76 to 112 mmHg) for MAP, 75 ± 7 mmHg (range, 61 to 87
mmHg) for DBP, and 63 ± 12 mmHg (range, 40 to 85
mmHg) for PP. The average postdialysis BPs were 153 ± 19
mmHg (range, 109 to 182 mmHg) for SBP, 104 ± 10
mmHg (range, 81 to 119 mmHg) for MAP, 80 ± 7 mmHg
(range, 67 to 96 mmHg) for DBP, and 73 ± 15 mmHg
(range, 42 to 102 mmHg) for PP.
Relationship between postdialysis BP rise and long-term
clinical outcomes
The mean follow-up time was 3.4 ± 1.4 years. By the cen-
soring date, 40 patients (35%) had died, of whom 18
(16%) were related to cardiovascular etiologies. The
causes of cardiovascular death were acute myocardial
infarction (7 patients), sudden cardiac arrest suspected
fatal arrhythmia (6 patients), critical aortic stenosis (3
patients), and stroke (2 patients). Among patients who
died due to non-cardiovascular mortality, the causes of
mortality were sepsis (16 patients), malignancy (4
patients), severe gastrointestinal bleeding (1 patient), and
hollow organ perforation (1 patient). Seven patients were
given kidney transplantations. Univariate Cox regression
analysis indicated that patients with an average postdialy-
sis SBP rise of more than 5 mmHg were more likely to
suffer from cardiovascular mortality (HR, 3.756 [95% CI,
1.454-9.703], p = 0.006) and all-cause mortality (HR,
2.382 [95% CI, 1.280-4.434], p = 0.006) than those with-
out. However, the variability of postdialysis SBP altera-
tion was not associated with all-cause mortality (HR,
0.949 [95% CI, 0.872-1.033], p =0 . 2 3 0 )o rc a r d i o v a s c u l a r
mortality (HR, 1.004 [95% CI, 0.908-1.109], p = 0.945).
Postdialysis SBP rise was associated with both
cardiovascular and all-cause mortality
Kaplan-Meier estimates showed a significantly greater
cardiovascular mortality rate for patients with an aver-
age postdialysis SBP rise of more than 5 mmHg than for
those with an average postdialysis SBP change between
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Factor All Patients with postdialytic
SBP rise > 5 mmHg
Patients with postdialytic SBP
change between -5 to 5 mmHg
Patients with postdialytic
SBP drop > 5 mmHg
p Value
Patient number 115 39 27 49
Age (year) 64.0 ± 13.6 68.6 ± 11.5 65.1 ± 16.0 59.6 ± 12.6 0.007*
Male gender (%) 45.2 41.0 33.3 55.1 0.153
Dialysis duration
(year)




22.0 ± 3.5 21.7 ± 3.4 21.9 ± 3.6 22.2 ± 3.5 0.840
Smoking index 0.46 ± 0.74 0.46 ± 0.79 0.41 ± 0.69 0.49 ± 0.74 0.900




40.0 43.6 37.0 38.8 0.844
Hypertension (%) 91.3 89.7 92.6 91.8 1.000
Cardiovascular
disease (%)
26.1 30.8 29.6 20.4 0.487
Prior stroke (%) 4.3 7.7 0.0 4.1 0.365




47.0 53.8 44.4 42.9 0.565
Antihypertensive
agents (%)
79.1 89.7 85.2 67.3 0.025*
Antiplatelet
agents (%)
33.0 41.0 33.3 26.5 0.356
Statins (%) 35.7 33.3 37.0 36.7 0.933
Fibrates (%) 7.0 10.3 3.7 6.1 0.719
Vitamin D3 (%) 19.1 15.4 18.5 22.4 0.702
Hepatitis B infection
(%)
7.8 7.7 0.0 12.2 0.172
Hepatitis C infection
(%)
18.3 12.8 25.9 18.4 0.409
Laboratory data
Albumin (g/dL) 4.1 ± 0.3 4.1 ± 0.3 4.2 ± 0.3 4.2 ± 0.3 0.224
Total cholesterol
(mg/dL)
173.5 ± 36.1 175.4 ± 35.0 171.1 ± 31.4 173.4 ± 39.9 0.895
Triglycerides
(mg/dL)
182.9 ± 125.2 166.6 ± 113.1 190.8 ± 145.1 191.4 ± 123.9 0.614
Sodium
(mmol/L)
139.8 ± 2.9 139.4 ± 2.9 139.9 ± 3.5 140.0 ± 3.1 0.693
Chloride
(mmol/L)
99.7 ± 2.5 100.1 ± 2.3 100.0 ± 2.6 99.1 ± 2.6 0.148
Bicarbonate
(mmol/L)
24.0 ± 2.5 24.1 ± 2.5 23.7 ± 2.3 24.1 ± 2.6 0.770
ALT (U/L) 20.4 ± 12.5 20.5 ± 12.1 23.0 ± 18.4 18.8 ± 8.0 0.460
Alk-P (mg/dL) 113.9 ± 61.5 117.3 ± 79.3 103.0 ± 42.4 117.1 ± 54.2 0.578
Fasting glucose
(mg/dL)
139.7 ± 66.6 143.3 ± 57.0 140.2 ± 75.8 136.4 ± 69.6 0.890
HbA1c (%) 6.2 ± 1.5 6.0 ± 1.1 6.0 ± 1.6 6.3 ± 1.8 0.573
WBC count (1000
per cumm)
6.3 ± 1.8 6.2 ± 1.6 6.4 ± 1.6 6.5 ± 2.0 0.741
Hemoglobin
(g/dL)
10.1 ± 1.3 9.7 ± 1.0 10.2 ± 1.6 10.3 ± 1.4 0.077
High-sensitive
CRP (mg/dL)
0.514 ± 0.706 0.573 ± 0.662 0.343 ± 0.305 0.562 ± 0.875 0.357
Ferritin (ng/mL) 510.3 ± 570.7 508.5 ± 541.1 595.1 ± 944.2 464.9 ± 229.4 0.723
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Page 4 of 10-5 to 5 mmHg (p = 0.030; log-rank test) and for those
with an average postdialysis SBP drop of more than 5
mmHg (p = 0.016; log-rank test) (Figure 3). In addition,
patients with an average postdialysis SBP rise of more
than 5 mmHg had a significantly higher all-cause mor-
tality rate than those with an average postdialysis SBP
change between -5 to 5 mmHg (p = 0.049; log-rank
test) and those with an average postdialysis SBP drop of
more than 5 mmHg (p = 0.011; log-rank test) (Figure 4).
Significant predictors of all-cause mortality by
multivariate Cox regression analysis
As shown in Table 2, initial univariate Cox regression
analysis of variables significantly associated with all-
cause mortality (p < 0.10) indicated that old age, male
gender, low Kt/V, diabetes mellitus, cardiovascular dis-
ease, underlying malignancy, hypoalbuminemia, high
fasting blood glucose, elevated high-sensitive C-reactive
protein (CRP), average postdialysis SBP rise of more
than 5 mmHg, large ultrafiltration volume, and high CT
ratio increased the risk. We included all these variables
in a multivariate Cox regression analysis. The result
indicated that old age, male gender, hypoalbuminemia,
elevated baseline high-sensitive CRP, large ultrafiltration
volume, high CT ratio, and average postdialysis SBP rise
of more than 5 mmHg were independent predictors of
4-year all-cause mortality.
Positive correlation between postdialysis SBP rise and
high CT ratio
As shown in Table 1, among patients with an average
postdialysis SBP rise of more than 5 mmHg, up to
Table 1 Demographic characteristics of the study population (Continued)
Transferrin
saturation (%)





143.1 ± 15.5 138.1 ± 16.6 141.5 ± 13.8 147.9 ± 14.3 0.009*
postdialytic SBP
(mmHg)
143.1 ± 17.1 152.6 ± 19.2 142.7 ± 14.5 135.7 ± 12.6 < 0.001*
predialytic DBP
(mmHg)
78.2 ± 6.8 74.9 ± 6.9 77.9 ± 5.8 81..0 ± 6.1 < 0.001*
postdialytic DBP
(mmHg)
79.1 ± 6.2 80.0 ± 6.8 79.6 ± 6.6 78.2 ± 5.4 0.345
predialytic MAP
(mmHg)
99.8 ± 9.1 96.0 ± 9.6 99.1 ± 7.7 103.3 ± 8.1 0.001*
postdialytic MAP
(mmHg)
100.5 ± 9.0 104.2 ± 10.1 100.6 ± 8.4 97.3 ± 7.2 0.001*
predialytic PP
(mmHg)
64.9 ± 11.4 63.2 ± 11.8 63.6 ± 11.1 67.0 ± 11.1 0.238
Postdialytic PP
(mmHg)
64.0 ± 13.8 72.6 ± 15.2 63.2 ± 11.4 57.5 ± 9.8 < 0.001*
Ultrafiltration volume
(Kg)
2.4 ± 0.8 2.1 ± 0.5 2.3 ± 0.9 2.6 ± 0.8 0.006*
CT ratio > 50% (%) 68.7 89.7 63.0 55.1 0.002*
Values are expressed as mean ± SD or percent unless otherwise listed. Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin II-receptor blocker;
ALT, alanine aminotransferase; Alk-P, alkaline phosphatase; HbA1c, glycosylated hemoglobin; WBC, white blood cell; CRP, C-reactive protein; SBP, systolic blood
pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; PP, pulse pressure; CT, cardiothoracic. *: p < 0.05.
Figure 1 Histogram of postdialysis SBP change of 2875 HD
sessions in 115 patients. Abbreviations: SBP, systolic blood
pressure; HD, hemodialysis.
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This showed that patients with an average postdialysis
SBP rise might be associated with subclinical volume
overload, and/or might suffer from cardiomyopathy. We
found a significant positive correlation between postdia-
lysis SBP rise and high CT ratio (r = 0.247, p =0 . 0 0 8 )
(Figure 5). However, there were still some patients with
a decline in SBP during HD had a high CT ratio. This is
consistent with the above findings of multivariate analy-
sis that both postdialysis SBP rise and high CT ratio are
independent outcome predictors.
Discussion
In chronic HD patients, there are three different time
periods for BP recordings: peridialysis, intradialysis, and
interdialysis [19]. The optimal BP of chronic HD
patients recommended by the KDOQI guidelines is
based on peridialysis BP, rather than intradialytic or
interdialysis BP [12]. Previous studies have shown a
reverse epidemiology association between absolute pre-
dialysis and postdialysis BP values and clinical outcomes
[18,20]. In the present study, we examined the relation-
ship between peridialysis BP alterations and outcomes,
which revealed that patients with an average postdialysis
SBP rise of more than 5 mmHg were more likely to suf-
fer from 4-year cardiovascular and all-cause mortality. A
higher CT ratio was also an independent long-term out-
come predictor in our study. This is consistent with pre-
vious studies which showed that a CT ratio of more
than 50% was associated with 2-year mortality in
chronic HD patients [21,22]. Meanwhile, we found that
among patients with an average postdialysis SBP rise of
more than 5 mmHg, up to 89.7% suffered from a high
CT ratio. This suggests that the prevalence of subclinical
fluid overload is high in chronic HD patients, and that
volume excess may manifest as postdialysis hyperten-
sion. Furthermore, previous outcome studies showing
that intradialytic hypertension was associated with 2-
year all-cause mortality did not examined cardiovascular
outcomes [1,4]. To the best of our knowledge, our study
is the first to demonstrate the positive correlation
between postdialysis SBP rises and long-term cardiovas-
cular mortality.
Our data also showed that among patients with post-
dialysis SBP rise, their MAP, DBP, and PP also rose
(Figure 2). However, after multivariate Cox regression
analysis, only SBP remained significant in predicting
outcomes. Patients with an average postdialysis SBP rise
of more than 5 mmHg carried a 2.9 times increased risk
for all-cause mortality than those without. Our results
are in accordance with a study conducted by Inrig et al.,
which reported that an increase in SBP of more than 10
mmHg during HD was associated with decreased 2-year
overall survival but was limited to patients with predia-
lysis SBP < 120 mmHg. Although their study was con-
ducted in a larger cohort of 1748 incident HD patients,
the baseline BP measurements were averaged from only
3 consecutive HD sessions [1]. In contrast, our results
were derived from the mean values of SBP recorded for
2 months. When plotting a histogram of postdialysis
SBP change for each patient, the histogram derived
from more times of HD sessions (n =2 5 )s h o u l dm o r e
closely resemble a normal distribution. Therefore,
patient grouping might be different while average post-
dialysis BP change was derived from different numbers
of HD times. Moreover, the averaged predialysis SBP of
the majority of our patients were more than 120 mmHg,
which might also explain why we did not find such pre-
dictive value when categorizing our patients by 10-
mmHg threshold.
Previous studies have shown that BP measured at the
44-hour interdialysis period, including ambulatory BP
monitoring and self-measurement by the patient using
home BP monitoring, correlates well with left
Figure 2 Predialysis and postdialysis blood pressure categorized by postdialysis SBP rise > 5 mmHg (n = 39) (A) and those with
postdialysis SBP drop > 5 mmHg (n = 49) (B). Abbreviations: HD, hemodialysis; SBP, systolic blood pressure; MAP, mean arterial pressure; DBP,
diastolic blood pressure; PP, pulse pressure. (*: p < 0.001).
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cular and all-cause mortality [14,16]. Although interdia-
lysis ambulatory BP measurement is of greater
prognostic value than HD unit BP recordings, it requires
equipment and is not readily available in most HD units
[19]. In addition, accurate self-measurement by the
patient using home BP monitoring during the interdialy-
sis period may be difficult for elderly and frail patients.
On the other hand, peridialysis BP measurements,
which are performed by dialysis unit staff shortly before
and after the HD session, are much easily assessible.
Furthermore, Van Buren et al. recently unveiled the
linkage between intradialytic hypertension and interdia-
lytic ambulatory BP burden. Their findings explain the
increased morbidity and mortality seen in patients with
intradialytic hypertension [23].
Although peridialysis BP recorded from 3-6 HD ses-
sions have been reported to be poorly correlated with
end-organ damage and cardiovascular outcomes [14-16],
the discrepancy was suggested to result from the highly
variable nature of peridialysis BP levels [19,24,25]. We
believe that a high variability of peridialysis BP record-
ings can be offset by increasing the number of recording
times. In addition, a previous study also showed that
average predialysis systolic BP taken more than 1 month
may be equally representative of the true BP than 24-
hour ambulatory BP monitoring [17]. Therefore, we sug-
gest that peridialysis BP averaged from 25 consecutive
HD sessions is more reproducible and practical to
reflect the actual postdialysis BP alterations in chronic
HD patients. On the other hand, categorizing patients
by a 5-mmHg interval which was averaged from a 2-
month BP data might hinder its clinical applicability.
Furthermore, it should be emphasized that a rise in
postdialysis SBP can not be concluded from one single
HD session BP recording.
There are emerging data showing that postdialysis
hypertension is associated with poor outcomes, but the
mechanisms of such poor outcomes remain poorly
understood [1,26]. Our results revealed that postdialysis
SBP rise was associated with fluid overload, as evidenced
by a higher CT ratio, lower ultrafiltration volume, and
lower hemoglobin level. Therefore, postdialysis SBP rise
may be an implication of volume excess. In patients suf-
fering from postdialysis hypertension, clinicians should
prudently assess their volume status and intensify fluid
removal as needed. Nevertheless, since both postdialysis
SBP rise and high CT ratio were independent outcome
predictors, there must be a mechanism other than
volume excess contributing to postdialysis hypertension,
such as elevated circulating endothelin and intradialytic
sodium load. Therefore, drugs that inhibit the renin-
angiotensin system, such as angiotensin converting
enzyme (ACE) inhibitors or angiotensin II-receptor
b l o c k e r s( A R B )s h o u l db ep r e ferred because they cause
greater regression of LVH, reduce sympathetic nerve
activity, reduce pulse wave velocity, may improve
endothelial function, and may reduce oxidative stress
[12].
Our multivariate analysis also revealed that high UF
volume had an independent association with mortality,
which was consistent with previous studies showing the
Figure 4 Hemodialysis patients with an average postdialysis
systolic blood pressure (SBP) rise of more than 5 mmHg were
at the highest risk for all-cause mortality, as compared to
those with an average postdialysis SBP change between -5 to
5 mmHg (p = 0.049; log-rank test) and those with an average
postdialysis SBP drop > 5 mmHg (p = 0.011; log-rank test).
Figure 3 Hemodialysis patients with an average postdialysis
systolic blood pressure (SBP) rise of more than 5 mmHg were
at the highest risk of cardiovascular mortality, as compared to
those with an average postdialysis SBP change between -5 to
5 mmHg (p = 0.030; log-rank test) and those with an average
postdialysis SBP drop > 5 mmHg (p = 0.016; log-rank test).
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hemodialysis patients
Factor Univariate Multivariate
HR 95% CI p Value HR 95% CI p Value
Lower Upper Lower Upper
Age (10 year) 1.713 1.284 2.286 < 0.001* 1.947 1.366 2.775 < 0.001
Male gender (%) 1.899 1.014 3.557 0.045* 4.267 1.985 9.171 < 0.001
Dialysis duration (year) 0.951 0.889 1.017 0.140
Body mass index (Kg/m
2) 1.000 0.914 1.093 0.995
Smoking index 1.167 0.795 1.712 0.430
Kt/V 0.116 0.033 0.416 0.001*
Comorbidities (%)
Diabetes mellitus (%) 2.125 1.138 3.967 0.018*
Hypertension (%) 1.352 0.417 4.388 0.615
Cardiovascular disease (%) 2.256 1.204 4.227 0.011*
Prior stroke (%) 2.588 0.797 8.406 0.114
Malignancy (%) 2.704 1.130 6.467 0.025*
Hepatitis B infection (%) 0.887 0.273 2.879 0.842
Hepatitis C infection (%) 0.896 0.376 2.135 0.805
Medications
Antihypertensive agents (%) 0.921 0.439 1.935 0.829
ACE inhibitor/ARB (%) 1.141 0.614 2.121 0.676
Vitamin D3 (%) 1.156 0.533 2.510 0.713
Laboratory data
Albumin (g/dL) 0.136 0.044 0.425 0.001* 0.032 0.008 0.126 < 0.001
Total cholesterol (mg/dL) 0.997 0.989 1.006 0.509
Triglycerides (mg/dL) 1.001 0.999 1.003 0.442
Sodium (mmol/L) 0.937 0.841 1.044 0.236
Chloride (mmol/L) 0.984 0.869 1.114 0.801
Bicarbonate (mmol/L) 0.959 0.851 1.082 0.497
ALT (U/L) 1.001 0.978 1.024 0.963
Alk-P (mg/dL) 1.000 0.995 1.005 0.927
Fasting glucose (mg/dL) 1.004 1.000 1.008 0.030*
HbA1c (%) 1.135 0.956 1.347 0.149
WBC count (1000 per cumm) 0.958 0.788 1.166 0.671
Hemoglobin (g/dL) 1.019 0.806 1.289 0.873
High-sensitive CRP (mg/dL) 1.432 1.062 1.932 0.019* 1.534 1.072 2.195 0.019
Ferritin (ng/mL) 1.000 1.000 1.001 0.743
Transferrin saturation (%) 0.826 0.065 10.479 0.883
Peridialytic BP
predialytic SBP (mmHg) 1.000 0.980 1.020 0.993
postdialytic SBP (mmHg) 1.008 0.990 1.026 0.393
predialytic MAP (mmHg) 0.992 0.959 1.027 0.648
postdialytic MAP (mmHg) 1.003 0.970 1.038 0.844
predialytic DBP (mmHg) 0.978 0.934 1.024 0.346
postdialytic DBP (mmHg) 0.981 0.932 1.032 0.452
predialytic PP (mmHg) 1.008 0.981 1.035 0.578
postdialytic PP (mmHg) 1.016 0.994 1.038 0.159
Peridialytic BP alterations (no as reference)
postdialytic SBP rise > 5 mmHg (yes/no) 2.382 1.280 4.434 0.006* 3.925 1.420 10.846 0.008
postdialytic MAP rise > 5 mmHg (yes/no) 1.762 0.929 3.344 0.083
postdialytic DBP rise > 5 mmHg (yes/no) 1.602 0.800 3.207 0.184
postdialytic PP rise > 5 mmHg (yes/no) 1.548 0.808 2.965 0.188
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weight gain [27,28]. However, we found patients with
postdialysis SBP rise had the lowest UF volume. As
mentioned above, this patient group may be volume
overloaded. It seems possible that volume excess in this
patient group was caused by low UF volume. However,
such interpretation was limited by the lack of assess-
ment of patient dry weight in our study. The present
data suggest that both high UF volume and postdialysis
SBP rise were both independent outcome predictors.
There are some limitations to our study. First, we did
not include intradialytic BP in our study. However, a post-
dialysis BP rise may be derived from intradialytic BP eleva-
tion. Second, the sample size of our cohort is relatively
small, but the BP values were averaged from 25 consecu-
tive HD sessions during a 2-month period. Third, the posi-
tive correlation between postdialysis SBP rise and volume
excess is cross-sectional rather than longitudinal. Fourth,
because of the non-randomized nature of our study
design, there is an excess of malignancy in the patient
group with a SBP rise. Nevertheless, the independent pre-
dictive value of postdialysis SBP rise was evidenced by the
multivariate analysis. Finally, the event rate was not opti-
mal for multivariate regression analysis because of the
relatively small patient number in the present study.
Therefore, further large scale longitudinal studies are
needed to investigate the impact of volume reduction on
postdialysis SBP alterations and patient outcomes.
Conclusions
The findings of the present study indicated that a rise in
postdialysis SBP in chronic HD patients was associated
with a higher risk of both long-term cardiovascular and
all-cause mortality throughout the 4 years of follow-up.
Since postdialysis BP rise might reflect subclinical
volume excess, we suggest intensive evaluation of
volume status in such patients in order to improve their
survival. In addition, future studies are warranted to
examine benefits of optimizing ACE inhibitor or ARB
use in patients with postdialysis SBP rises.
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